Synergy Pharmaceuticals Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range
52-Week Range N/A
Average Volume6.08 million shs
Market Capitalization$7.44 million
P/E RatioN/A
Dividend YieldN/A

Receive SGYP News and Ratings via Email

Sign-up to receive the latest news and ratings for Synergy Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Synergy Pharmaceuticals logo

About Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.99 out of 5 stars

Medical Sector

1583rd out of 2,220 stocks

Pharmaceutical Preparations Industry

696th out of 869 stocks

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Synergy Pharmaceuticals (NASDAQ:SGYP) Frequently Asked Questions

What stocks does MarketBeat like better than Synergy Pharmaceuticals?

Wall Street analysts have given Synergy Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Synergy Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Synergy Pharmaceuticals' earnings last quarter?

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) released its quarterly earnings data on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.01. The biopharmaceutical company earned $11.11 million during the quarter, compared to analysts' expectations of $15.65 million.
View Synergy Pharmaceuticals' earnings history

Who are Synergy Pharmaceuticals' key executives?

Synergy Pharmaceuticals' management team includes the following people:
  • Mr. Troy Hamilton Pharm.D., CEO & Director (Age 47)
  • Mr. Gary G. Gemignani, Exec. VP & CFO (Age 54)
  • Gem Gokmen Hopkins, VP of Investor Relations and Corp. Communications
  • Ms. Pamela Cebulski, Sr. VP of Marketing
  • Ms. Marianne Jackson, Sr. VP of Sales & Market Access

Who are some of Synergy Pharmaceuticals' key competitors?

What other stocks do shareholders of Synergy Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Synergy Pharmaceuticals investors own include Novavax (NVAX), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), Inovio Pharmaceuticals (INO), ACADIA Pharmaceuticals (ACAD), Cara Therapeutics (CARA), OPKO Health (OPK), Gilead Sciences (GILD), Exelixis (EXEL) and (SLS).

What is Synergy Pharmaceuticals' stock symbol?

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

How much money does Synergy Pharmaceuticals make?

Synergy Pharmaceuticals has a market capitalization of $0.00 and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.

What is Synergy Pharmaceuticals' official website?

The official website for Synergy Pharmaceuticals is

Where are Synergy Pharmaceuticals' headquarters?

Synergy Pharmaceuticals is headquartered at 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170.

How can I contact Synergy Pharmaceuticals?

Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected]

This page was last updated on 8/1/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.